Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, and Hepatocellular Carcinoma

Williams, 2011, Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study, Gastroenterology, 140, 124, 10.1053/j.gastro.2010.09.038

Rinella, 2014, Controversies in the diagnosis and management of NAFLD and NASH, Gastroenterol Hepatol (N Y), 10, 219

Harrison, 2003, The natural history of nonalcoholic fatty liver disease: a clinical histopathological study, Am J Gastroenterol, 98, 2042, 10.1111/j.1572-0241.2003.07659.x

El-Serag, 2007, Hepatocellular carcinoma: epidemiology and molecular carcinogenesis, Gastroenterology, 132, 2557, 10.1053/j.gastro.2007.04.061

Seefe, 2004, Introduction: the burden of hepatocellular carcinoma, Gastroenterology, 127, S1, 10.1053/j.gastro.2004.09.010

Wong, 2014, Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S, Hepatology, 59, 2188, 10.1002/hep.26986

Welzel, 2013, Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States, Am J Gastroenterol, 108, 1314, 10.1038/ajg.2013.160

Calle, 2003, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults, N Engl J Med, 348, 1625, 10.1056/NEJMoa021423

Moller, 1994, Obesity and cancer risk: a Danish record-linkage study, Eur J Cancer, 30A, 344, 10.1016/0959-8049(94)90254-2

Wolk, 2001, A prospective study of obesity and cancer risk (Sweden), Cancer Causes Control, 12, 13, 10.1023/A:1008995217664

Oh, 2005, Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study, J Clin Oncol, 23, 4742, 10.1200/JCO.2005.11.726

Larsson, 2007, Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies, Br J Cancer, 97, 1005, 10.1038/sj.bjc.6603932

Ohki, 2009, Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH, Gut, 58, 839, 10.1136/gut.2008.164053

Lazo, 2008, The epidemiology of nonalcoholic fatty liver disease: a global perspective, Semin Liver Dis, 28, 339, 10.1055/s-0028-1091978

Adami, 1996, Excess risk of primary liver cancer in patients with diabetes mellitus, J Natl Cancer Inst, 88, 1472, 10.1093/jnci/88.20.1472

El-Serag, 2004, Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma, Gastroenterology, 126, 460, 10.1053/j.gastro.2003.10.065

Wideroff, 1997, Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark, J Natl Cancer Inst, 89, 1360, 10.1093/jnci/89.18.1360

Yang, 2011, The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies, PLoS One, 6, e27326, 10.1371/journal.pone.0027326

Wang, 2011, Prognostic role of diabetes mellitus in hepatocellular carcinoma patients after curative treatments: a meta-analysis, Hepatobiliary Pancreat Dis Int, 10, 346, 10.1016/S1499-3872(11)60059-3

Wang, 2014, Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis, PLoS One, 9, e95485, 10.1371/journal.pone.0095485

Neuschwander-Tetri, 2003, Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference, Hepatology, 37, 1202, 10.1053/jhep.2003.50193

Ratziu, 2002, Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis, Hepatology, 35, 1485, 10.1053/jhep.2002.33324

Siegel, 2009, Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link, Cancer, 115, 5651, 10.1002/cncr.24687

Ekstedt, 2006, Long-term follow-up of patients with NAFLD and elevated liver enzymes, Hepatology, 44, 865, 10.1002/hep.21327

Rafiq, 2009, Long-term follow-up of patients with nonalcoholic fatty liver, Clin Gastroenterol Hepatol, 7, 234, 10.1016/j.cgh.2008.11.005

Adams, 2005, The natural history of nonalcoholic fatty liver disease: a population-based cohort study, Gastroenterology, 129, 113, 10.1053/j.gastro.2005.04.014

Sanyal, 2010, Population-based risk factors and resource utilization for HCC: US perspective, Curr Med Res Opin, 26, 2183, 10.1185/03007995.2010.506375

Ascha, 2010, The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis, Hepatology, 51, 1972, 10.1002/hep.23527

Bhala, 2011, The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study, Hepatology, 54, 1208, 10.1002/hep.24491

Zen, 2001, Hepatocellular carcinoma arising in non-alcoholic steatohepatitis, Pathol Int, 51, 127, 10.1046/j.1440-1827.2001.01174.x

Orikasa, 2001, Lipid-rich clear-cell hepatocellular carcinoma arising in non-alcoholic steatohepatitis in a patient with diabetes mellitus, J Submicrosc Cytol Pathol, 33, 195

Bencheqroun, 2004, Hepatocellular carcinoma without cirrhosis in a patient with nonalcoholic steatohepatitis, Gastroenterol Clin Biol, 28, 497, 10.1016/S0399-8320(04)94971-8

Bullock, 2004, Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma, J Hepatol, 41, 685, 10.1016/j.jhep.2004.05.008

Gonzalez, 2004, Obesity as a risk factor for hepatocellular carcinoma in a noncirrhotic patient, Semin Liver Dis, 24, 415, 10.1055/s-2004-860870

Cuadrado, 2005, Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma, Obes Surg, 15, 442, 10.1381/0960892053576596

Sato, 2005, Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid, Virchows Arch, 447, 996, 10.1007/s00428-005-0042-z

Hai, 2006, Hepatocellular carcinoma arising from nonalcoholic steatohepatitis: report of two cases, Surg Today, 36, 390, 10.1007/s00595-005-3167-4

Ichikawa, 2006, Two cases of non-alcoholic steatohepatitis with development of hepatocellular carcinoma without cirrhosis, J Gastroenterol Hepatol, 21, 1865, 10.1111/j.1440-1746.2006.04282.x

Hashizume, 2007, Primary liver cancers with nonalcoholic steatohepatitis, Eur J Gastroenterol Hepatol, 19, 827, 10.1097/MEG.0b013e3282748ef2

Guzman, 2008, Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?, Arch Pathol Lab Med, 132, 1761, 10.5858/132.11.1761

Chagas, 2009, Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients?, Braz J Med Biol Res, 42, 958, 10.1590/S0100-879X2009005000019

Paradis, 2009, Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis, Hepatology, 49, 851, 10.1002/hep.22734

Kawada, 2009, Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis, J Gastroenterol, 44, 1190, 10.1007/s00535-009-0112-0

Hashimoto, 2009, Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis, J Gastroenterol, 44, 89, 10.1007/s00535-008-2262-x

Takuma, 2010, Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review, World J Gastroenterol, 16, 1436, 10.3748/wjg.v16.i12.1436

Tokushige, 2010, Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C, J Gastroenterol, 45, 960, 10.1007/s00535-010-0237-1

Yasui, 2011, Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma, Clin Gastroenterol Hepatol, 9, 428, 10.1016/j.cgh.2011.01.023

Wakai, 2011, Surgical outcomes for hepatocellular carcinoma in nonalcoholic fatty liver disease, J Gastrointest Surg, 15, 1450, 10.1007/s11605-011-1540-8

Ikura, 2011, Hepatocellular carcinomas can develop in simple fatty livers in the setting of oxidative stress, Pathology, 43, 167, 10.1097/PAT.0b013e32834274ec

Arase, 2012, Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients, Hepatol Res, 42, 264, 10.1111/j.1872-034X.2011.00915.x

Mittal, 2015, Temporal trends of non-alcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population, Clin Gastroenterol Hepatol, 13, 594, 10.1016/j.cgh.2014.08.013

Ertle, 2011, Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis, Int J Cancer, 128, 2436, 10.1002/ijc.25797

Michelotti, 2013, NAFLD, NASH and liver cancer, Nat Rev Gastroenterol Hepatol, 10, 656, 10.1038/nrgastro.2013.183

Grundy, 2004, Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition, Circulation, 109, 433, 10.1161/01.CIR.0000111245.75752.C6

Harrison, 2006, Liver disease in patients with diabetes mellitus, J Clin Gastroenterol, 40, 68, 10.1097/01.mcg.0000190774.91875.d2

Balkau, 2001, Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites: the Paris prospective study, Diabetes Care, 24, 843, 10.2337/diacare.24.5.843

Moore, 1998, Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts, Eur J Cancer Prev, 7, 89

Kaburagi, 1999, The mechanism of insulin-induced signal transduction mediated by the insulin receptor substrate family, Endocr J, S25, 10.1507/endocrj.46.Suppl_S25

Kim, 1996, Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product, Cancer Res, 56, 3831

Tanaka, 1997, Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes, Hepatology, 26, 598, 10.1002/hep.510260310

Tanaka, 1996, Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis, Cancer Res, 56, 3391

Saito, 2002, Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma, Gut, 51, 100, 10.1136/gut.51.1.100

Peyrou, 2010, PTEN in liver diseases and cancer, World J Gastroenterol, 16, 4627, 10.3748/wjg.v16.i37.4627

Puri, 2008, Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease, Gastroenterology, 134, 568, 10.1053/j.gastro.2007.10.039

Hirosumi, 2002, A central role for JNK in obesity and insulin resistance, Nature, 420, 333, 10.1038/nature01137

Chang, 2009, Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer, J Hepatol, 50, 323, 10.1016/j.jhep.2008.07.037

Hui, 2008, Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation, J Clin Invest, 118, 3943, 10.1172/JCI37156

Schattenberg, 2006, JNK1 but not JNK2 promotes the development of steatohepatitis in mice, Hepatology, 43, 163, 10.1002/hep.20999

Abdelmalek, 2009, Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial, Hepatology, 50, 1818, 10.1002/hep.23239

Fujishita, 2011, JNK signaling promotes intestinal tumorigenesis through activation of mTOR complex 1 in Apc(Delta716) mice, Gastroenterology, 140, 1556, 10.1053/j.gastro.2011.02.007

Zhou, 2010, The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma, Med Oncol, 27, 255, 10.1007/s12032-009-9201-4

Rinella, 2011, Dysregulation of the unfolded protein response in db/db mice with diet-induced steatohepatitis, Hepatology, 54, 1600, 10.1002/hep.24553

Henkel, 2013, The unfolded protein response in fatty liver disease, Semin Liver Dis, 33, 321, 10.1055/s-0033-1358522

Dai, 2009, Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells, Int J Oncol, 34, 1749

Ozcan, 2004, Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes, Science, 306, 457, 10.1126/science.1103160

Xu, 2005, Endoplasmic reticulum stress: cell life and death decisions, J Clin Invest, 115, 2656, 10.1172/JCI26373

Kharroubi, 2004, Free fatty acids and cytokines induce pancreatic beta-cell apoptosis by different mechanisms: role of nuclear factor-kappaB and endoplasmic reticulum stress, Endocrinology, 145, 5087, 10.1210/en.2004-0478

Vandewynckel, 2013, The paradox of the unfolded protein response in cancer, Anticancer Res, 33, 4683

Shuda, 2003, Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis, J Hepatol, 38, 605, 10.1016/S0168-8278(03)00029-1

Zhang, 2011, Role of nuclear receptor SHP in metabolism and cancer, Biochim Biophys Acta, 1812, 893, 10.1016/j.bbadis.2010.10.006

Pikarsky, 2004, NF-kappaB functions as a tumour promoter in inflammation-associated cancer, Nature, 431, 461, 10.1038/nature02924

Hu, 2002, The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma, Carcinogenesis, 23, 1781, 10.1093/carcin/23.11.1781

Taylor, 2001, Regulation of the G2/M transition by p53, Oncogene, 20, 1803, 10.1038/sj.onc.1204252

Xu, 2005, Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia, Proc Natl Acad Sci U S A, 102, 4120, 10.1073/pnas.0500660102

Maki, 2007, Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma, Ann Surg Oncol, 14, 1182, 10.1245/s10434-006-9049-1

Kelesidis, 2010, Narrative review: the role of leptin in human physiology: emerging clinical applications, Ann Intern Med, 152, 93, 10.7326/0003-4819-152-2-201001190-00008

Tilg, 2010, Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis, Hepatology, 52, 1836, 10.1002/hep.24001

Dotsch, 2005, New insights into leptin resistance by modifying cytokine receptor signal transduction, Eur J Endocrinol, 152, 333, 10.1530/eje.1.01859

Wang, 2004, Potential involvement of leptin in carcinogenesis of hepatocellular carcinoma, World J Gastroenterol, 10, 2478, 10.3748/wjg.v10.i17.2478

Fruhbeck, 2006, Intracellular signalling pathways activated by leptin, Biochem J, 393, 7, 10.1042/BJ20051578

Ramani, 2008, Leptin's mitogenic effect in human liver cancer cells requires induction of both methionine adenosyltransferase 2A and 2beta, Hepatology, 47, 521, 10.1002/hep.22064

Friedman, 2000, Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury, J Biol Chem, 275, 2247, 10.1074/jbc.275.4.2247

Lu, 2012, S-adenosylmethionine in liver health, injury, and cancer, Physiol Rev, 92, 1515, 10.1152/physrev.00047.2011

Mato, 2013, S-adenosylmethionine metabolism and liver disease, Ann Hepatol, 12, 183, 10.1016/S1665-2681(19)31355-9

Chen, 2007, Identification of a key pathway required for the sterile inflammatory response triggered by dying cells, Nat Med, 13, 851, 10.1038/nm1603

Takeuchi, 2010, Pattern recognition receptors and inflammation, Cell, 140, 805, 10.1016/j.cell.2010.01.022

Zhang, 2010, Circulating mitochondrial DAMPs cause inflammatory responses to injury, Nature, 464, 104, 10.1038/nature08780

Seki, 2008, Toll-like receptors and adaptor molecules in liver disease: update, Hepatology, 48, 322, 10.1002/hep.22306

Yu, 2010, Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents, Hepatology, 52, 1322, 10.1002/hep.23845

Dapito, 2012, Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4, Cancer Cell, 21, 504, 10.1016/j.ccr.2012.02.007

Hosaka, 2013, Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection, Hepatology, 58, 98, 10.1002/hep.26180

Bjorkhem-Bergman, 2014, Statin treatment reduces the risk of hepatocellular carcinoma but not colon cancer-results from a nationwide case-control study in Sweden, Pharmacoepidemiol Drug Saf, 23, 1101, 10.1002/pds.3685

El-Serag, 2009, Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes, Gastroenterology, 136, 1601, 10.1053/j.gastro.2009.01.053

Kawata, 2001, Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial, Br J Cancer, 84, 886, 10.1054/bjoc.2000.1716

Cao, 2011, MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase, Cancer Res, 71, 2286, 10.1158/0008-5472.CAN-10-3367

Spampanato, 2012, Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression, Int J Oncol, 40, 935, 10.3892/ijo.2011.1273

Gao, 2010, Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice, J Int Med Res, 38, 1413

Singh, 2013, Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis, Am J Gastroenterol, 108, 881, 10.1038/ajg.2013.5

Donadon, 2010, Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease, Liver Int, 30, 750, 10.1111/j.1478-3231.2010.02223.x

Donadon, 2010, Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma, World J Gastroenterol, 16, 3025, 10.3748/wjg.v16.i24.3025

Wang, 2012, Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis, Diabetes Metab Res Rev, 28, 109, 10.1002/dmrr.1291

Chen, 2011, Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation, J Gastroenterol Hepatol, 26, 858, 10.1111/j.1440-1746.2011.06664.x

Lai, 2012, Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study, Am J Gastroenterol, 107, 46, 10.1038/ajg.2011.384

Hassan, 2010, Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma, Cancer, 116, 1938, 10.1002/cncr.24982

Bhat, 2013, The mTOR pathway in hepatic malignancies, Hepatology, 58, 810, 10.1002/hep.26323

Lu, 2009, S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model, Hepatology, 50, 462, 10.1002/hep.22990

Anstee, 2012, S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility, J Hepatol, 57, 1097, 10.1016/j.jhep.2012.04.041